Last reviewed · How we verify
NCT04262830: CATCH-HF
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
trial testing Cardiac magnetic resonance imaging (MRI) in Cardiotoxicity in 150 participants. Currently enrolling.
30 September 2028
Quick facts
| Lead sponsor | Hari Narayan |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 30 September 2019 |
| Primary completion | 30 September 2028 |
| Estimated completion | 30 September 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cardiac magnetic resonance imaging (MRI)
- Accelerometer physical activity monitoring
Conditions studied
- Cardiotoxicity — all drugs for Cardiotoxicity →
- Pediatric Cancer — all drugs for Pediatric Cancer →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Hari Narayan
Who can join
Adults 13 to 39, any sex, with Cardiotoxicity or Pediatric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging Strategies for the Prevention of Chemotherapy-Induced Cardiotoxicity in Paediatric Cancer Patients: Advances and Future Perspectives.
Pozza A, Di Candia A, Zanella L, Stefors EJ, et al · · 2025 · cited 1× · PMID 41304849 · DOI 10.3390/ph18111604
Verify or expand the search:
- PubMed search for NCT04262830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiotoxicity
Currently open trials in the same condition.
- NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
- NCT06778122 — In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors · NA · recruiting
- NCT07382141 — Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age · NA · recruiting
- NCT06595147 — Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study · NA · recruiting
- NCT06270667 — Effects of Exercise Training in Survivors of Lymphoma · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04262830 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hari Narayan
- Last refreshed: 28 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04262830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing